DRW Securities LLC Invests $4.74 Million in Keros Therapeutics, Inc. $KROS

Key Points

• DRW Securities LLC acquired a new stake in Keros Therapeutics, buying 464,895 shares worth approximately $4.74 million, representing 1.14% of the company as of the latest reporting period.
• Multiple hedge funds have significantly increased their stakes in Keros Therapeutics, with Federated Hermes Inc. leading at a 882.3% increase during the first quarter.
• Analysts have set new price targets for Keros Therapeutics, with Bank of America downgrading the stock and reducing its target from $32.00 to $18.00 amid mixed ratings from seven investment analysts.

DRW Securities LLC acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 464,895 shares of the company's stock, valued at approximately $4,737,000. DRW Securities LLC owned 1.14% of Keros Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC raised its position in Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock valued at $237,000 after purchasing an additional 2,384 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Keros Therapeutics in the first quarter valued at about $25,000. CWM LLC raised its holdings in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after buying an additional 2,641 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Keros Therapeutics by 35.5% during the fourth quarter. ProShare Advisors LLC now owns 10,549 shares of the company's stock worth $167,000 after buying an additional 2,764 shares during the period. Finally, Brevan Howard Capital Management LP grew its holdings in shares of Keros Therapeutics by 95.6% during the fourth quarter. Brevan Howard Capital Management LP now owns 11,186 shares of the company's stock worth $177,000 after buying an additional 5,468 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

NASDAQ:KROS traded up $0.51 during trading hours on Tuesday, hitting $15.72. The company's stock had a trading volume of 475,978 shares, compared to its average volume of 489,741. The business's 50-day moving average is $14.26 and its two-hundred day moving average is $13.23. The company has a market capitalization of $638.55 million, a PE ratio of 50.71, a PEG ratio of 1.96 and a beta of 1.06. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same period in the previous year, the firm earned ($1.25) EPS. The business's revenue was up 49002.7% on a year-over-year basis. As a group, analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. HC Wainwright cut their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wedbush reaffirmed a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, Scotiabank dropped their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $30.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.